



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
(CIN:L24232GJ1996PLC029894)



Date: 26 October 2021

Ref No:-TCPCL/SEC/2021-22/00033

To,

| | |
|---|--|
| The General Manager, Corporate relationship department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001 Scrip Code: 543321 Through: BSE Corporate Compliance & Listing Centre | The Manager, Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra-Kurla, Complex Bandra(E), Mumbai-400 051 Scrip Symbol: TATVA Through: NEAPS |
|---|--|

Dear Sir/Madam,

Sub: Press Release on the financial results

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on the financial results of the Company for the quarter and half year ended 30 September 2021.

The same will also be available on the Company's website, 'www.tatvachintan.com'.

This is for your information and records.

Yours faithfully,

For Tatva Chintan Pharma Chem Limited



Apurva Dubey
Company Secretary and Compliance Officer
Membership No: A-41130



RESULT PRESS RELEASE

Tatva Chintan Pharma Chem Limited Reports 2Q FY22 Financial Results

Vadodara, 26 October 2021: Tatva Chintan Pharma Chem Limited (TCPCL) BSE: 543321, NSE: TATVA, an integrated speciality chemical company, has announced its financial results for the second quarter and half year ended on 30 September 2021, as approved by the Board of Directors.

Results at Glance (Y-O-Y - 2Q FY22 COMPARED WITH 2Q FY21)

- **Revenue from Operations** for the quarter was ₹ 1,236.15 million higher by 106%
- **EBITDA** for the quarter was ₹ 386.98 million higher by 365%
- **EBIDTA Margin** for the quarter was at 31.31% higher by 1,746 bps
- **Net Profit** for the quarter was ₹ 324.12 million higher by 811%
- **Net Profit Margin** for the quarter was at 25.64% higher by 1990 bps
- **Basic and Diluted EPS** for the quarter was ₹ 15.02 per share, increased by 749%

Results at Glance (Y-O-Y – 1H FY22 COMPARED WITH 1H FY21)

- **Revenue from Operations** for the half year was ₹ 2,304.47 million higher by 107%
- **EBITDA** for the half year was ₹ 662.96 million higher by 242%
- **EBIDTA Margin** for the half year was at 28.77% higher by 1,138 bps
- **Net Profit** for the half year was ₹ 555.58 million higher by 441%
- **Net Profit Margin** for the half year was at 23.64% higher by 1,466 bps
- **Basic and Diluted EPS** for the half year was ₹ 26.7 per share, increased by 422%

Commenting on the Q2 & H1 performance Mr. Chintan Shah, Managing Director, said, as we have announced our results just before Diwali; I take this opportunity to wish each one of you a very Happy Diwali and Prosperous New year, let us hope we all have a wonderful, successful & most importantly a healthy year ahead.

I am pleased to inform you that we have reported a historically record-breaking performance in 2QFY22; we are very well on our way of being recognized as a niche player in the speciality chemical space with our focus on manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts, Pharma & Agrochemical Intermediates and Speciality Chemicals. We have a clear focus on adopting green chemistry processes supported by our state-of-the-art research and development facility and manufacturing plants. With the wide range of applications of our products, TCPCL can cater to customers across wide spectrum of chemical Industries which ensures a sustainable business model. Diversified product portfolio has helped accelerate our growth. We recently got listed on NSE/BSE on 29 July 2021, out of our net IPO proceeds of ₹ 2,072.81 million, ₹ 396.85 million have been utilized as on 30 September 2021. The capacity expansion is underway at our Dahej SEZ manufacturing plant and at our R&D facility at Vadodara.



RESULT PRESS RELEASE

About Tatva Chintan Pharma Chem Limited (TCPCL):

TCPCL is an Integrated Specialty Chemical company, present across the value chain manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts and Pharma & Agrochemical Intermediates and Specialty Chemicals, established in the year 1996 by first generation entrepreneur engineers. It has two manufacturing facilities at Ankleshwar and Dahej SEZ, Gujarat with an existing combined installed reactor capacity of 280KL and 29 Assembly Lines, having Sophisticated R&D Unit recognized by DSIR at Vadodara, Gujarat. TCPCL has a customer base spanning over 25 Countries including USA, UK, China, Germany, Japan and South Africa. Exports constitute 71% of the total revenue. The Company is focused on serving customers across broad spectrum of chemical industries with applications in automotive, petrochemicals, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care and flavors & fragrances. For more information on Tatva Chintan, please visit: www.tatvachintan.com

Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward looking statements are subject to several known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward - looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Tatva Chintan Pharma Chem Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For Further details, please get in touch with:

Dinesh Sodani

Tatva Chintan Pharma Chem Limited
Email: finance1@tatvachintan.com

Krishna Patel / Rahul Thakkar

Christensen Advisory
kpatel@christensenir.com/
rthakur@christensenir.com